Evidence map›Paper›PMID 40448295›Full record

ArticleAging cell2025

Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus.

Caroline Hoong, Joshua N Farr, David G Monroe, Thomas A White, Elizabeth J Atkinson, Amanda Tweed, Allyson K Palmer, Nathan K LeBrasseur, Jad G Sfeir, Sundeep Khosla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Caroline HoongDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Joshua N FarrDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
David G MonroeDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Thomas A WhiteRobert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota, USA.
Elizabeth J AtkinsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Amanda TweedDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Allyson K PalmerRobert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota, USA.
Nathan K LeBrasseurRobert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota, USA.
Jad G SfeirDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-1576-1534
Sundeep KhoslaDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-2936-4372

Funding

Targeting Cellular Senescence to Extend HealthspanP01AG062413 · NIA · MAYO CLINIC ROCHESTER · PI Sundeep Khosla, Nathan K LeBrasseur · 2019 to 2026
$28.7M
Defining the interactions of senescent immune cells and skeletal cellsR01AG076515 · NIA · MAYO CLINIC ROCHESTER · PI Sundeep Khosla, David G Monroe · 2022 to 2026
$2.4M
Targeting Cellular Senescence and RAGE in Type 2 DiabetesR01DK128552 · NIDDK · UNIVERSITY OF ARIZONA · PI FARR, JOSHUA NICHOLAS · 2021 to 2025
$2.0M
Characterization of senescent cell populations in skeletal agingR01AG086085 · NIA · MAYO CLINIC ROCHESTER · PI Sundeep Khosla, David G Monroe · 2024 to 2026
$1.6M
Hevolution HR-GRO-23-1199144-8NIA NIH HHS AG062413NIA NIH HHS AG076515NIA NIH HHS AG086085NIA NIH HHS P01 AG062413NIA NIH HHS R01 AG076515NIA NIH HHS R01 AG086085NIDDK NIH HHS DK128552NIDDK NIH HHS R01 DK128552
6 · The paper itself

Abstract

Although animal studies have linked cellular senescence to the pathogenesis and complications of type 2 diabetes mellitus (T2DM), there is a paucity of corroborating data in humans. Thus, we measured a previously validated marker for senescent cell burden in humans, T-cell expression of p16 mRNA, along with additional biomarkers, to compare the senescence phenotypes of postmenopausal control (lean, N = 37) and T2DM (N = 27) participants. To control for effects of obesity alone, we included a third group of obese but non-diabetic women (N = 29) who were matched for body mass index to the T2DM participants. In addition, given the increase in fracture risk in T2DM despite preserved or even increased bone mineral density, we related these senescence biomarkers in the T2DM participants to skeletal microarchitectural parameters. Relative to the lean participants, T-cell p16 and p21

Indexed as

BiomarkersCellular SenescenceDiabetes Mellitus, Type 2AgedCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21FemaleHumansMiddle AgedObesityBiomarkersCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21agingdiabetesobesityosteoporosissenescence

Identifiers

PMID40448295
PMCPMC12341793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.